Jonathan Leff, M.D. has served as our Senior Vice President and Chief Medical Officer since February 2016. Previously Dr. Leff served as Executive Vice President, Research and Development at InterMune from February 2012 until its acquisition by Roche/Genentech in March 2015. At InterMune, Dr. Leff oversaw the development and approval of Esbriet® for the treatment of idiopathic pulmonary fibrosis in the United States. Prior to InterMune, Dr. Leff served as Chief Medical Officer at KaloBios Pharmaceuticals from 2011 to 2012, and also served as Vice President and Chief Medical Officer at Halozyme Therapeutics from 2009 to 2010. From 2007 to 2009, Dr. Leff was Vice President and Global Head of Inflammation Clinical Development at Roche, where he managed the worldwide clinical development programs for MabThera®/Rituxan®, ocrelizumab, and Actemra®. From 2002 to 2007, Dr. Leff held various positions at Amgen, including Vice President, North American Medical Affairs. From 1994 to 2002, Dr. Leff served at Merck developing and commercializing Singulair®. Dr. Leff trained in Internal Medicine, Pulmonary and Critical Care at the University of Colorado in Denver and served in various positions, including director of the Outpatient Pulmonary Clinic. Dr. Leff holds a B.A. in Chemistry from the University of Pennsylvania, and received his M.D. from the University of Pennsylvania School of Medicine.

 Management